Targeted use of heparin, heparinoids, or low-molecular-weight heparin to improve outcome after acute ischaemic stroke: An individual patient data meta-analysis of randomised controlled trials

The Lancet Neurology

Volumn 12, Issue 6, 2013, Pages 539-545

  Whiteley, William N ^a   Adams, Harold P ^b   Bath, Philip M W ^c   Berge, Eivind ^d   Sandset, Per Morten ^d   Dennis, Martin ^a   Murray, Gordon D ^a   Wong, Ka Sing Lawrence ^e   Sandercock, Peter A G ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; DALTEPARIN; DANAPAROID; HEPARIN; HEPARINOID; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PLACEBO; TINZAPARIN;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CLINICAL EVALUATION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; DRUG USE; FEMALE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MORTALITY; NEUROLOGIC DISEASE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; STROKE PATIENT; TREATMENT OUTCOME; TREATMENT RESPONSE;

BRAIN ISCHEMIA; DRUG DELIVERY SYSTEMS; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HEPARINOIDS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE;

EID: 84877921154     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(13)70079-6     Document Type: Article

References (38)

1. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380:2095-2128.
2. Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380:2163-2196.
3. Kumar S, Selim MH, Caplan LR Medical complications after stroke. Lancet Neurol 2010, 9:105-118.
4. Balami JS, Chen RL, Grunwald IQ, Buchan AM Neurological complications of acute ischaemic stroke. Lancet Neurol 2011, 10:357-371.
5. Geeganage CM, Sprigg N, Bath MW, Bath PMW Balance of symptomatic pulmonary embolism and symptomatic intracerebral hemorrhage with low-dose anticoagulation in recent ischemic stroke: a systematic review and meta-analysis of randomized controlled trials. J Stroke Cerebrovas Dis 2013, 10.1016/j.jstrokecerebrovasdis.2012.03.005.
6. Sandercock PA, Counsell C, Kamal AK Anticoagulants for acute ischaemic stroke. Cochrane Database Syst Rev 2008, CD000024. DOI:10.1002/14651858.CD000024.pub3.
7. Bath PMW, Iddenden R, Bath FJ Low-molecular-weight heparins and heparinoids in acute ischemic stroke: a meta-analysis of randomized controlled trials. Stroke 2000, 31:1770-1778.
8. Bath P, Leonardi-Bee J, Bath F Low molecular weight heparin versus aspirin for acute ischemic stroke: A systematic review. J Stroke Cerebrovas Dis 2002, 11:55-62.
9. Al-Sadat A, Sunbulli M, Chaturvedi S Use of intravenous heparin by North American neurologists. Stroke 2002, 33:1574-1577.
10. Caplan LR Resolved: heparin may be useful in selected patients with brain ischemia. Stroke 2003, 34:230-231.
11. Kang K, Dong WK, Park HK, Yoon BW Optimal dosing of intravenous unfractionated heparin bolus in transient ischemic attack or stroke. Clin Appl Thromb Hemost 2010, 16:126-131.
12. Mokin M, Kass-Hout T, Kass-Hout O, et al. Intravenous heparin for the treatment of intraluminal thrombus in patients with acute ischemic stroke: a case series. J NeuroIntervent Surg 2012, 10.1136/neurintsurg-2011-010134.
13. Schmidt WP, Heuschmann P, Taeger D, Henningsen H, Buecker-Nott HJ, Berger K Determinants of IV heparin treatment in patients with ischemic stroke. Neurology 2004, 63:2407-2409.
14. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet 2012, 379:2352-2363. IST-3 collaborative group.
15. Cordonnier C, Leys D, Deplanque D, Henon H Antithrombotic agents' use in patients with atrial fibrillation and acute cerebral ischemia. J Neurol 2006, 253:1076-1082.
16. Duffy BK, Phillips PA, Davis SM, Donnan GA, Vedadhaghi ME Evidence-based care and outcomes of acute stroke managed in hospital specialty units. Med J Aust 2003, 178:318-323.
17. Eriksson M, Stecksen A, Glader EL, et al. Discarding heparins as treatment for progressive stroke in Sweden 2001 to 2008. Stroke 2010, 41:2552-2558.
18. Grau AJ, Eicke M, Biegler MK, et al. Quality monitoring of acute stroke care in Rhineland-Palatinate, Germany, 2001-2006. Stroke 2010, 41:1495-1500.
19. Sett A, Mistri AK A dramatic impact of CLOTS Studies on clinical practice in the UK. Int J Stroke 2011, 6:15.
20. Management of patients with stroke or TIA: assessment, investigation, immediate management and secondary prevention 2008, Scottish Intercollegiate Guideline Network, Scottish Intercollegiate Guidelines Network, Edinburgh.
21. NICE. Venous thromboembolism: reducing the risk. NICE Clinical Guideline 2010; 92.
22. Dennis M, Sandercock P, Reid J, et al. Can clinical features distinguish between immobile patients with stroke at high and low risk of deep vein thrombosis? Statistical modelling based on the CLOTS trials cohorts. J Neurol Neurosurg Psychiatry 2011, 82:1067-1073.
23. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group. Lancet 1997, 349:1569-1581. International Stroke Trial Collaborative Group.
24. Sandercock P, Niewada M, Czlonkowska A The international stroke trial database. Trials 2011, 12:101. the International Stroke Trial Collaborative Group.
25. Low molecular weight heparinoid, ORG 10172 (Danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial. JAMA 1998, 279:1265-1272. The Publications Committee for the Trial of ORG.
26. Bath PM, Lindenstrom E, Boysen G, et al. Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial. Lancet 2001, 358:702-710.
27. Berge E, Abdelnoor M, Nakstad PH, Sandset PM Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. Lancet 2000, 355:1205-1210.
28. Wong KS, Chen C, Ng PW, et al. Low-molecular-weight heparin compared with aspirin for the treatment of acute ischaemic stroke in Asian patients with large artery occlusive disease: a randomised study. Lancet Neurol 2007, 6:407-413.
29. Gray LJ, Ali M, Lyden PD, Bath PMW Interconversion of the National Institutes of Health Stroke Scale and Scandinavian Stroke Scale in Acute Stroke. J Stroke Cerebrovas Dis 2009, 18:466-468.
30. Bamford J, Sandercock P, Dennis M, Warlow C, Burn J Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet 1991, 337:1521-1526.
31. Lindley RI. Are very large trials of promising treatments for acute stroke feasible? [MD thesis] University of Newcastle-upon-Tyne, UK; 1993.
32. Altman DG, Royston P What do we mean by validating a prognostic model?. Statist Med 2000, 19:453-473.
33. Rubin DB Multiple imputation for nonresponse in surveys 1987, John Wiley & Sons.
34. Can we improve the statistical analysis of stroke trials?. Stroke 2007, 38:1911-1915. The Optimising Analysis of Stroke Trials (OAST) Collaboration.
35. Geraghty OC, Mehta Z, Rothwell PM Population based study of predictors of bleeding on aspirin-based antiplatelet treatment: towards a risk model. Cerebrovasc Dis 2012, 33(suppl 2):49.
36. Wijnhoud AD, Maasland L, Lingsma HF, Steyerberg EW, Koudstaal PJ, Dippel DWJ Prediction of major vascular events in patients with transient ischemic attack or ischemic stroke: a comparison of 7 models. Stroke 2010, 41:2178-2185.
37. Kumar S, Selim MH, Caplan LR Medical complications after stroke. Lancet Neurol 2010, 9:105-118.
38. Qaseem A, Chou R, Humphrey LL, Starkey M, Shekelle P Venous thromboembolism prophylaxis in hospitalized patients: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2011, 155:625-632.